Hoerger, T.J.* ; Hilscher, R.* ; Neuwahl, S.* ; Kaufmann, M.B.* ; Shao, H.* ; Laxy, M. ; Cheng, Y.J.* ; Benoit, S.* ; Chen, H.* ; Anderson, A.* ; Craven, T.* ; Yang, W.* ; Cintina, I.* ; Staimez, L.* ; Zhang, P.*
A new type 2 diabetes microsimulation model to estimate long-term health outcomes, costs, and cost-effectiveness.
Value Health 26, 1372-1380 (2023)
Seidl, H. ; Schunk, M.* ; Le, L.* ; Syunyaeva, Z.* ; Streitwieser, S.* ; Berger, U.* ; Mansmann, U.* ; Szentes, B.L. ; Bausewein, C.* ; Schwarzkopf, L.
Cost-effectiveness of a specialized breathlessness service versus usual care for patients with advanced diseases.
Value Health 26, 81-90 (2023)
Böckmann, D. ; Szentes, B.L. ; Schultz, K.* ; Nowak, D.* ; Schuler, M.* ; Schwarzkopf, L.
Cost-effectiveness of pulmonary rehabilitation in patients with bronchial asthma: An analysis of the EPRA randomized controlled trial.
Value Health 24, 1254-1262 (2021)
Laxy, M. ; Becker, J. ; Kähm, K. ; Holle, R. ; Peters, A. ; Thorand, B. ; Schwettmann, L. ; Karl, F.
Utility decrements associated with diabetes and related complications: Estimates from a population-based study in Germany.
Value Health 24, 274-280 (2021)
Shao, H.* ; Laxy, M. ; Gregg, E.W.* ; Albright, A.* ; Zhang, P.*
Cost-effectiveness of the new 2018 American college of physicians glycemic control guidance statements among US adults with type 2 diabetes.
Value Health 24, 227-235 (2021)
Maqhuzu, P.N. ; Szentes, B.L. ; Kreuter, M.* ; Bahmer, T.* ; Kahn, N.C.* ; Claussen, M.* ; Holle, R. ; Schwarzkopf, L.
Predictors of health-related quality of life decline in intersitial lung disease using the K-bild questionnaire.
Value Health 23, S360-S360 (2020)
Kirsch, F. ; Schramm, A.* ; Schwarzkopf, L. ; Szentes, B.L. ; Lutter, J. ; Huber, M.B. ; Leidl, R.
Influence of COPD severity and its comorbidities on direct and indirect costs: Results from the LQ-DMP study.
Value Health 22, S876-S876 (2019)
Maqhuzu, P.N. ; Kreuter, M.* ; Schwarzkopf, L.
Cost of healthcare resource utilization in interstitial lung diseases in Germany in 2017.
Value Health 22, S845-S845 (2019)
Szentes, B.L. ; Schwarzkopf, L. ; Schüler, M.* ; Lehbert, N.* ; Nowak, D.* ; Wittmann, M.* ; Faller, H.* ; Schultz, K.*
The suitablility of the EQ-5D-5L in asthma patients.
Value Health 22, S882-S882 (2019)
Arnold, M. ; Quante, A.S.
Personalized mammography screening and screening adherence-A simulation and economic evaluation.
Value Health 21, 799-808 (2018)
Szentes, B.L. ; Kirsch, F. ; Schramm, A.* ; Schwarzkopf, L. ; Leidl, R.
Association between severe, moderate and mild exacerbations with generic health-related quality of life in COPD patients.
Value Health 21, S419-S419 (2018)
Walter, J. ; Schwarzkopf, L.
First insights into comparing expenditures for targeted therapy and survival in NSCLC.
Value Health 21, S35-S35 (2018)
Arnold, M.* ; Quante, A.S.
Risk-stratified breast cancer screening and non-adherence in Germany.
Value Health 20, A442-A442 (2017)
Hoogendoorn, M.* ; Feenstra, T.L.* ; Asukai, Y.* ; Briggs, A.H.* ; Hansen, R.N.* ; Leidl, R. ; Risebrough, N.* ; Samyshkin, Y.* ; Wacker, M.* ; Rutten-van Mölken, M.P.*
External validation of health economic decision models for chronic obstructive pulmonary disease (COPD): Report of the third COPD modeling meeting.
Value Health 20, 397-403 (2017)
Kirsch, F.* ; Becker, C. ; Maier, W. ; Schramm, A.*
Effects of adherence to pharmacological secondary prevention after myocardial infarction on healthcare expenditures.
Value Health 20, A609-A609 (2017)
Laxy, M. ; Wilson, E.C.F.* ; Boothby, C.E.* ; Griffin, S.J.*
Incremental costs and cost-effectiveness of intensive treatment in individuals with type 2 diabetes detected by screening in the ADDITION-UK trial: An update with empirical trial-based cost data.
Value Health 20, 1288-1298 (2017)
Leidl, R. ; Reitmeir, P.
An experience-based value set for the EQ-5D-5L in Germany.
Value Health 20, 1150-1156 (2017)
Seidl, H. ; Hunger, M. ; Meisinger, C. ; Kirchberger, I. ; Kuch, B.* ; Leidl, R. ; Holle, R.
The 3-year cost-effectiveness of a nurse-based case management versus usual care for elderly patients with myocardial infarction: Results from the KORINNA follow-up study.
Value Health 20, 441-450 (2017)
Szentes, B.L. ; Kreuter, M.* ; Bahmer, T.* ; Birring, S.* ; Claussen, M.* ; Waelscher, J.* ; Schwarzkopf, L.
Quality of life assessment in ILD - a comparison of  EQ-5D with the disease-specific K-bild.
Value Health 20, A649-A649 (2017)
Walter, J. ; Tufman, A.* ; Holle, R. ; Schwarzkopf, L.
Comparison of costs and care of lung cancer patient at the end-of-life in Germany depending on the tome of survival after diagnosis.
Value Health 20, A511-A511 (2017)
Arnold, M.* ; Quante, A.S.
Personalized mammography screening and screening adherence - a simulation of cost-effectiveness.
Value Health 19, A738-A738 (2016)
Danner, M.* ; Müller, D.* ; Schmutzler, R.K.* ; Rhiem, K.* ; Engel, C.* ; Stollenwerk, B. ; Stock, S.* ; Wassermann, K.*
Economic modeling of risk-adapted screen-and-treat strategies in women at high-risk for breast or ovarian cancer.
Value Health 19, A737-A738 (2016)
Hoogendoorn, M.* ; Feenstra, T.* ; Asukai, Y.* ; Briggs, A.* ; Borg, S.* ; dal Negro, R.* ; Hansen, R.N.* ; Jansson, S.A.* ; Leidl, R. ; Risebrough, N.* ; Samyshkin, Y.* ; Wacker, M. ; Rutten van-Mölken, M.*
Patient heterogeneity in health economic decision models for Chronic Obstructive Pulmonary Disease: Are current models suitable to evaluate personalized medicine?.
Value Health 19, 800-810 (2016)
Kirsch, F.
Economic evaluations of multicomponent disease management programs with Markov models: A systematic review.
Value Health 19, 1039-1054 (2016)
Leidl, R. ; Reitmeir, P.
Analyzing a German index for the EQ-5D-5L based on experienced health.
Value Health 19, A386-A386 (2016)
Szentes, B.L. ; Witt, S. ; Bush, A.* ; Cunningham, S.* ; Emiraliouglu, N.* ; Goldbeck, L.* ; Griese, M.* ; Hengst, M.* ; Kiper, N.* ; Krenke, K.* ; Lange, J.* ; Leidl, R. ; Schwerk, N.* ; Schwarzkopf, L.
Current practice of drug treatment in children with ILD: First insights from the child-EU registry.
Value Health 19, A558-A558 (2016)
Walter, J. ; Vogl, M. ; Holderried, M.* ; Becker, C. ; Brandes, A. ; Sinner, M.F.* ; Rogowski, W.H. ; Maschmann, J.*
Manual compression versus vascular closing device for closing access puncture site in femoral left-heart catheterization and percutaneous coronary interventions: A retrospective cross-sectional comparison of costs and effects in inpatient care.
Value Health 20, 769-776 (2016)
Hoogendoorn, M.* ; Feenstra, T.* ; Asukai, Y.* ; Briggs, A.* ; Borg, S.* ; dal Negro, R.* ; Hansen, R.N.* ; Jansson, S.A.* ; Wacker, M. ; Risebrough, N.* ; Samyshkin, Y.* ; Leidl, R. ; Rutten van-Mölken, M.*
Patient heterogeneity in cost-effectiveness models for Chronic Obstructive Pulmonary Disease (COPD): Are current models suitable to evaluate personalized medicine.
Value Health 18:A694 (2015)
Laxy, M. ; Hunger, M. ; Stark, R.G. ; Meisinger, C. ; Kirchberger, I. ; Heier, M. ; von Scheidt, W.* ; Holle, R.
The burden of diabetes mellitus in patients with coronary heart disease: A methodological approach to assess quality-adjusted life-years based on individual-level longitudinal survey data.
Value Health 18, 969-976 (2015)
Brandes, A. ; Koerber, F. ; Schwarzkopf, L. ; Hunger, M. ; Waidelich, R.* ; Rogowski, W.H.
Cost-effectiveness of radical prostatectomy, radiation therapy and active surveillance for the treatment of localized prostate cancer - a claims data analysis.
Value Health 17, A636-A637 (2014)
Butzke, B. ; Oduncu, F.* ; Heinemann, V.* ; Pfeufer, A. ; Giessen, C.* ; Stollenwerk, B. ; Rogowski, W.H.
Cost-effectiveness analysis of ugt1a1 genotyping before colorectal cancer treatment with irinotecan.
Value Health 17, A643 (2014)
Hoogendoorn, M.* ; Feenstra, T.L.* ; Asukai, Y.* ; Borg, S.* ; Hansen, R.N.* ; Jansson, S.A.* ; Samyshkin, Y.* ; Wacker, M. ; Briggs, A.H.* ; Lloyd, A.* ; Sullivan, S.D.* ; Rutten-van Mölken, M.P.*
Cost-effectiveness models for chronic obstructive pulmonary disease: Cross-model comparison of hypothetical treatment scenarios.
Value Health 17, 525-536 (2014)
Hoogendoorn, M.* ; Feenstra, T.* ; Asukai, Y.* ; Borg, S.* ; Hansen, R.N.* ; Jansson, S.A.* ; Samyshkin, Y.* ; Wacker, M. ; Briggs, A.* ; Lloyd, A.* ; Sullivan, S.D.* ; Rutten-van Moelken, M.P.*
Cost-effectiveness models for Chronic Obstructive Pulmonary Disease (COPD): Cross-model comparison of hypothetical treatment scenarios.
Value Health 17, A557-A558 (2014)
Laxy, M. ; Hunger, M. ; Thorand, B. ; Meisinger, C. ; Kirchberger, I.* ; Holle, R.
The intermediate burden of diabetes mellitus in patients with cardiovascular disease (CVD): A quality adjusted life year (QALY) - analysis based on primary longitudinal data.
Value Health 17, A494 (2014)
Little, M.H.R. ; Reitmeir, P. ; Peters, A. ; Leidl, R.
The impact of differences between patient and general population EQ-5D-3L values on the mean tariff scores of different patient groups.
Value Health 17, 364-371 (2014)
Rochau, U.* ; Kuhner, F.* ; Jahn, B.* ; Kurzthaler, C.* ; Ramos, C.* ; Chhatwal, J.* ; Stollenwerk, B. ; Goldhaber-Fiebert, J.D.* ; Siebert, U.*
Prioritization of future outcomes research studies in chronic myeloid leukemia: Value of information analysis.
Value Health 17, A639 (2014)
Leidl, R. ; Reitmeir, P. ; König, H.-H.* ; Stark, R.G.
The performance of a value set for the EQ-5D based on experienced health states in patients with inflammatory bowel disease.
Value Health 15, 151-157 (2012)
Menn, P. ; Holle, R. ; Kunz, S. ; Donath, C.* ; Lauterberg, J.* ; Leidl, R. ; Marx, P.* ; Mehlig, H.* ; Ruckdäschel, S.* ; Vollmar, H.C.* ; Wunder, S.* ; Gräßel, E.*
Dementia care in the general practice setting: A cluster randomized trial on the effectiveness and cost impact of three management strategies.
Value Health 15, 851-859 (2012)
Rottenkolber, D. ; Hasford, J.* ; Stausberg, J.*
Costs of adverse drug events in German hospitals - a microcosting study.
Value Health 15, 868-875 (2012)
Hunger, M. ; Baumert, J.J. ; Holle, R.
Analysis of SF-6D index data: Is beta regression appropriate?
Value Health 14, 759-767 (2011)
Schwarzkopf, L. ; Menn, P. ; Kunz, S. ; Holle, R. ; Lauterberg, J.* ; Marx, P.* ; Mehlig, H.* ; Wunder, S.* ; Leidl, R. ; Donath, C.* ; Graessel, E.*
Costs of care for dementia patients in community setting: An analysis for mild and moderate disease stage.
Value Health 14, 827-835 (2011)
Schweikert, B.* ; John, J. ; Ringborg, A.* ; Erhardt, W.* ; Bleckmann, A.* ; Neubauer, A.S.*
Standards for the assessment of antidiabetic drugs-the IQWIG perspectice.
Value Health 13, A300-A300 (2010)
Happich, M. ; Moock, J.* ; von Lengerke, T.
Health state valuation methods and reference points: The case of tinnitus.
Value Health 12, 88-95 (2009)
Graf von der Schulenburg, J.M.* ; Greiner, W.* ; Jost, F.* ; Klusen, N.* ; Kubin, M.* ; Leidl, R. ; Mittendorf, T.* ; Rebscher, H.* ; Schoeffski, O.* ; Vauth, C.* ; Volmer, T.* ; Wahler, S.* ; Wasem, J.* ; Weber, C.* ; Hanover Consensus Group (*)
German recommendations on health economic evaluation: Third and updated version of the Hanover Consensus.
Value Health 11, 539-544 (2008)